First and second doses of Covishield vaccine provided high level of protection against SARS-CoV-2 infection in highly transmissible settings: results from a prospective cohort of participants residing in congregate facilities in India.
First and second doses of Covishield vaccine provided high level of protection against SARS-CoV-2 infection in highly transmissible settings: results from a prospective cohort of participants residing in congregate facilities in India.
复制标题
Covishield疫苗的第一剂和第二剂疫苗在高度传播的环境中为SARS-COV-2感染提供了高水平的保护：来自居住在印度聚集设施中的一群参与者的结果。
DOI：
10.1136/bmjgh-2021-008271
复制
发表时间：
2022-05
影响因子：
8.1
通讯作者：
Dorjee, Kunchok
中科院分区：
文献类型：
--
作者：
Tsundue, Tenzin;Namdon, Tenzin;Tsewang, Tenzin;Topgyal, Sonam;Dolma, Tashi;Lhadon, Dekyi;Choetso, Tsering;Woesal, Tenzin;Yangkyi, Tenzin;Gupta, Amita;Peters, David;Paster, Zorba;Phunkyi, Dawa;Sadutshang, Tsetan Dorji;Chaisson, Richard E.;Dorjee, Kunchok
本研究旨在确定Covishield疫苗在聚集居住设施居民中的有效性。集合住宅设施的前瞻性队列研究。2020年12月至2021年7月，印度喜马偕尔邦达兰萨拉。七个设施（三座寺院、两座养老院和两个学习中心）的所有年龄段的居民都参加了。预防SARS-CoV-2感染的Covishield疫苗第一剂和第二剂。主要结局是COVID-19的发展。次要结局为不利结局，定义为呼吸短促、住院或死亡的复合结局。疫苗有效性（%）计算为（1-HR）×100。共有1114名居民（中位年龄31岁）参与了这项研究，其中82%为男性。28%（n=308/1114）未接种疫苗，50%（n=554/1114）接受了一剂Covishield，23%（n=252/1114）接受了两剂Covishield。该等设施的COVID-19点流行率介乎11%至57%。COVID-19的发病率（95%CI）在未接种疫苗的人群中为76（63至90）/1000人月，在接种一剂疫苗的人群中为25（18至35）/1000人月，在接种两剂疫苗的人群中为9（4至19）/1000人月。第一剂和第二剂Covishield的有效率为71%（校正HR（aHR）0.29; 95% CI 0.18至0.46; p<0.001）和80%（aHR 0.20; 95% CI 0.09至0.44; p<0.001），分别针对SARS-CoV-2感染和86%（aHR 0.24; 95% CI 0.07 - 0.82; p=0.023）和99%（aHR 0.01; 95% CI 0.002 - 0.10; p<0.001）。在接受第一次和第二次剂量14天后，有效性分别为93%和98%。慢性B型肝炎患者（aHR 1.78; p=0.034）和既往结核病史患者（aHR 1.62; p=0.047）的感染风险较高。Covishield在Delta变异体驱动的第二波大流行期间有效预防SARS-CoV-2感染并降低高传播环境中的疾病严重程度。
This study aimed to determine the effectiveness of Covishield vaccine among residents of congregate residential facilities. A prospective cohort study in congregate residential facilities. Dharamshala, Himachal Pradesh, India, from December 2020 to July 2021. Residents of all ages in seven facilities—three monasteries, two old age homes and two learning centres—were enrolled. First and second doses of Covishield vaccine against SARS-CoV-2 infection. Primary outcome was development of COVID-19. Secondary outcome was unfavourable outcomes, defined as a composite of shortness of breath, hospitalisation or death. Vaccine effectiveness (%) was calculated as (1−HR)×100. There were 1114 residents (median age 31 years) participating in the study, 82% males. Twenty-eight per cent (n=308/1114) were unvaccinated, 50% (n=554/1114) had received one dose and 23% (n=252/1114) had received two doses of Covishield. The point prevalence of COVID-19 for the facilities ranged from 11% to 57%. Incidence rates (95% CI) of COVID-19 were 76 (63 to 90)/1000 person-months in the unvaccinated, 25 (18 to 35)/1000 person-months in recipients of one dose and 9 (4 to 19)/1000 person-months in recipients of two doses. The effectiveness of first and second doses of Covishield were 71% (adjusted HR (aHR) 0.29; 95% CI 0.18 to 0.46; p<0.001) and 80% (aHR 0.20; 95% CI 0.09 to 0.44; p<0.001), respectively, against SARS-CoV-2 infection and 86% (aHR 0.24; 95% CI 0.07 to 0.82; p=0.023) and 99% (aHR 0.01; 95% CI 0.002 to 0.10; p<0.001), respectively, against unfavourable outcome. The effectiveness was higher after 14 days of receiving the first and second doses, 93% and 98%, respectively. Risk of infection was higher in persons with chronic hepatitis B (aHR 1.78; p=0.034) and previous history of tuberculosis (aHR 1.62; p=0.047). Covishield was effective in preventing SARS-CoV-2 infection and reducing disease severity in highly transmissible settings during the second wave of the pandemic driven by the Delta variant.
登录
查看更多内容
DOI：
10.1016/s0140-6736(21)00432-3
发表时间：
2021-03-06
期刊：
Lancet (London, England)
影响因子：
--
作者：
Voysey M;Costa Clemens SA;Madhi SA;Weckx LY;Folegatti PM;Aley PK;Angus B;Baillie VL;Barnabas SL;Bhorat QE;Bibi S;Briner C;Cicconi P;Clutterbuck EA;Collins AM;Cutland CL;Darton TC;Dheda K;Dold C;Duncan CJA;Emary KRW;Ewer KJ;Flaxman A;Fairlie L;Faust SN;Feng S;Ferreira DM;Finn A;Galiza E;Goodman AL;Green CM;Green CA;Greenland M;Hill C;Hill HC;Hirsch I;Izu A;Jenkin D;Joe CCD;Kerridge S;Koen A;Kwatra G;Lazarus R;Libri V;Lillie PJ;Marchevsky NG;Marshall RP;Mendes AVA;Milan EP;Minassian AM;McGregor A;Mujadidi YF;Nana A;Padayachee SD;Phillips DJ;Pittella A;Plested E;Pollock KM;Ramasamy MN;Ritchie AJ;Robinson H;Schwarzbold AV;Smith A;Song R;Snape MD;Sprinz E;Sutherland RK;Thomson EC;Török ME;Toshner M;Turner DPJ;Vekemans J;Villafana TL;White T;Williams CJ;Douglas AD;Hill AVS;Lambe T;Gilbert SC;Pollard AJ;Oxford COVID Vaccine Trial Group
通讯作者：
Oxford COVID Vaccine Trial Group
DOI：
10.15585/mmwr.mm7038e1
发表时间：
2021-09-24
期刊：
MMWR. Morbidity and mortality weekly report
影响因子：
--
作者：
Self WH;Tenforde MW;Rhoads JP;Gaglani M;Ginde AA;Douin DJ;Olson SM;Talbot HK;Casey JD;Mohr NM;Zepeski A;McNeal T;Ghamande S;Gibbs KW;Files DC;Hager DN;Shehu A;Prekker ME;Erickson HL;Gong MN;Mohamed A;Henning DJ;Steingrub JS;Peltan ID;Brown SM;Martin ET;Monto AS;Khan A;Hough CL;Busse LW;Ten Lohuis CC;Duggal A;Wilson JG;Gordon AJ;Qadir N;Chang SY;Mallow C;Rivas C;Babcock HM;Kwon JH;Exline MC;Halasa N;Chappell JD;Lauring AS;Grijalva CG;Rice TW;Jones ID;Stubblefield WB;Baughman A;Womack KN;Lindsell CJ;Hart KW;Zhu Y;Mills L;Lester SN;Stumpf MM;Naioti EA;Kobayashi M;Verani JR;Thornburg NJ;Patel MM;IVY Network
通讯作者：
IVY Network
DOI：
10.1056/nejmoa2110345
发表时间：
2021-11-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Thomas SJ;Moreira ED Jr;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Polack FP;Zerbini C;Bailey R;Swanson KA;Xu X;Roychoudhury S;Koury K;Bouguermouh S;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Yang Q;Liberator P;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Gruber WC;Jansen KU;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
影响因子：
3.7
作者：
Inoue K;Kashima S
通讯作者：
Kashima S
DOI：
10.1016/s0140-6736(21)00677-2
发表时间：
2021-05-01
期刊：
Lancet (London, England)
影响因子：
--
作者：
Vasileiou E;Simpson CR;Shi T;Kerr S;Agrawal U;Akbari A;Bedston S;Beggs J;Bradley D;Chuter A;de Lusignan S;Docherty AB;Ford D;Hobbs FR;Joy M;Katikireddi SV;Marple J;McCowan C;McGagh D;McMenamin J;Moore E;Murray JL;Pan J;Ritchie L;Shah SA;Stock S;Torabi F;Tsang RS;Wood R;Woolhouse M;Robertson C;Sheikh A
通讯作者：
Sheikh A